Dietary supplementation with creatine in patients with kidney disease

Dietary supplementation with creatine in patients with kidney disease - CreaKidney

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00035761

Enrollment

Registered

2025-06-04

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18.89

Interventions

Group 1: Arm 1: Patients with chronic kidney disease without creatine supplementation (control phase) Patients with chronic kidney disease may have overt or latent creatine deficiency due to reduced

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Inclusion criteria for study participants in groups 1 and 3 (group 1: “Patients with chronic kidney disease”; group 3: “Healthy control subjects”) are additionally age 18–60 years, (relatively) good general health, and normal nutritional status. • For group 1, “Patients with chronic kidney disease,” a glomerular filtration rate of 20–50 ml/min/1.73 m2 is an additional requirement for inclusion. • For group 2, “Patients with chronic kidney disease due to aggregate-forming GATM mutations,” the presence of an aggregate-forming GATM mutation is a prerequisite for inclusion.

Exclusion criteria

Exclusion criteria: • Metabolic disorders • Liver disease • Body mass index 35 • Muscular or nervous system disorders • Gastrointestinal disorders • Heart disease • Arterial hypertension • Malignant disorders • Psychiatric disorders • Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
There are no endpoints in the traditional sense in this study. Therefore, the objectives of the study are included here: 1. Study objective “Creatine metabolism and kidney function” Investigation of creatine metabolism prior to supplementation and the effects of supplementation with creatine (at least 3 months) on creatine metabolism and kidney function in patients with chronic kidney disease, in patients with chronic kidney disease due to aggregate-forming GATM mutations, and in healthy individuals, as well as dose determination (for creatine) in individuals with impaired kidney function. Parameters recorded (3x without creatine supplementation, at least 3x with creatine supplementation): Creatine, guanidoacetate, creatinine, glucose, and amino acids in serum and urine GFR estimation by creatinine and cystatin C clearance 2. Study objective “well-being” Investigation of the effects of creatine supplementation on the well-being of patients with chronic kidney disease, patients with chronic kidney disease caused by aggregate-forming GATM mutations, and healthy individuals. Measurement method: Questionnaire without creatine supplementation and after 3 months of creatine supplementation 3. Study objective: “Slowing the progression of the disease in patients with aggregate-forming GATM mutations” Investigation of the effects of creatine supplementation on the progression of kidney disease in patients with chronic kidney disease caused by aggregate-forming GATM mutations. Parameters recorded (3x without creatine supplementation, at least 3x with creatine supplementation): GFR estimation by creatinine and cystatin C clearance Measurement of amino acid, protein, glucose, and phosphate excretion	—

Measure

Time frame

There are no endpoints in the traditional sense in this study. Therefore, the objectives of the study are included here: 1. Study objective “Creatine metabolism and kidney function” Investigation of creatine metabolism prior to supplementation and the effects of supplementation with creatine (at least 3 months) on creatine metabolism and kidney function in patients with chronic kidney disease, in patients with chronic kidney disease due to aggregate-forming GATM mutations, and in healthy individuals, as well as dose determination (for creatine) in individuals with impaired kidney function. Parameters recorded (3x without creatine supplementation, at least 3x with creatine supplementation): Creatine, guanidoacetate, creatinine, glucose, and amino acids in serum and urine GFR estimation by creatinine and cystatin C clearance 2. Study objective “well-being” Investigation of the effects of creatine supplementation on the well-being of patients with chronic kidney disease, patients with chronic kidney disease caused by aggregate-forming GATM mutations, and healthy individuals. Measurement method: Questionnaire without creatine supplementation and after 3 months of creatine supplementation 3. Study objective: “Slowing the progression of the disease in patients with aggregate-forming GATM mutations” Investigation of the effects of creatine supplementation on the progression of kidney disease in patients with chronic kidney disease caused by aggregate-forming GATM mutations. Parameters recorded (3x without creatine supplementation, at least 3x with creatine supplementation): GFR estimation by creatinine and cystatin C clearance Measurement of amino acid, protein, glucose, and phosphate excretion

—

Countries

Germany, United Kingdom, United States

Contacts

Public ContactRichard Warth

Universität Regensburg, Medizinische Zellbiologie

richard.warth@ur.de+49 941 943 2894

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026